DiaMedica Therapeutics Inc. (DMAC) Revenue by Segment & Business Profile

Recombinant human tissue kallikrein-1 (DM199) for acute ischemic stroke was 70.0% of DiaMedica Therapeutics Inc.'s revenue across the 4 lines it reports, according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

DMACDiaMedica Therapeutics Inc.Follow DMAC — free

Drug Manufacturers - General · Healthcare

—

Price chart with a free account

Market cap: 470.2M
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 18 Nov, in 25 days

What the company does

DiaMedica Therapeutics Inc. is a drug manufacturers - general company in the healthcare sector. In its SEC filings it reports 4 business lines: Recombinant human tissue kallikrein-1 (DM199) for acute ischemic stroke (70%), Recombinant human tissue kallikrein-1 (DM199) for preeclampsia (15%), Recombinant human tissue kallikrein-1 (DM199) for cardio renal disease (10%), Recombinant human tissue kallikrein-1 (DM199) for fetal growth restriction (5%).

Roles we read

from the filings, not the sector label

Large-cap pharmaceuticals

DiaMedica Therapeutics Inc. — questions

What does DiaMedica Therapeutics Inc. do?: DiaMedica Therapeutics Inc. is a drug manufacturers - general company in the healthcare sector. In its SEC filings it reports 4 business lines: Recombinant human tissue kallikrein-1 (DM199) for acute ischemic stroke (70%), Recombinant human tissue kallikrein-1 (DM199) for preeclampsia (15%), Recombinant human tissue kallikrein-1 (DM199) for cardio renal disease (10%), Recombinant human tissue kallikrein-1 (DM199) for fetal growth restriction (5%).
How does DiaMedica Therapeutics Inc. make money?: By the lines it reports in its SEC filings: Recombinant human tissue kallikrein-1 (DM199) for acute ischemic stroke 70.0%, Recombinant human tissue kallikrein-1 (DM199) for preeclampsia 15.0%, Recombinant human tissue kallikrein-1 (DM199) for cardio renal disease 10.0%, Recombinant human tissue kallikrein-1 (DM199) for fetal growth restriction 5.0% of revenue.

Every figure on this page comes from DiaMedica Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.